Back to top
more

Insmed (INSM)

(Delayed Data from NSDQ)

$71.69 USD

71.69
1,091,267

-1.17 (-1.61%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $72.05 +0.36 (0.50%) 5:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Insmed (INSM) Reliance on International Sales: What Investors Need to Know

by Zacks Equity Research

Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates

by Zacks Equity Research

INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.

Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -6.72% and 0.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCG

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VTWG

Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VTWO

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWO

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for BBSC

Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWM

Insmed Stock Surges 168% in the Past Six Months: Here's Why

by Zacks Equity Research

Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

by Zacks Equity Research

Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.

Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insmed (INSM) delivered earnings and revenue surprises of -59.02% and 2.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

by Zacks Equity Research

Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.

Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates

by Zacks Equity Research

Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.

Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.